Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

InMed Pharmaceuticals Shares Soar 1022% in 1 Day Since Financial Results

InMed Pharmaceuticals Q1 2026 Results: Net Loss Widens to $2.33 Million

+1022.70% in 1 day $1.63 when we broke this story → $18.30 peak on 4 Nov 2026

InMed Pharmaceuticals reported a widening net loss for the first quarter of fiscal 2026 as it continues to fund its cannabinoid-based drug pipeline. The company is currently focused on a pending merger with Mentari Therapeutics and securing a substantial cash runway to support operations through 2029.

Laboratory, equipment, vials, black and white. Stock photo illustrating InMed Pharmaceuticals' financial results story.
InMed Pharmaceuticals Inc. · Photo: zactucker / Pixabay
Results at a glance · $ Million
Metric Q1-26Q1-25
Pretax Income -2.00-1.83
Net Income -2.33-1.73
Diluted EPS -0.42-0.44
Net Income YoY
-35.0%

Key highlights

  • Net loss widened by 35.0% year-over-year to $2.33 million in Q1-26
  • Pretax income decreased to -$2.00 million from -$1.83 million in the prior-year period
  • Diluted earnings per share improved slightly to -$0.42 compared to -$0.44 in Q1-25
  • Company reaffirmed expected gross proceeds of $490.0 million from pre-closing financing
  • Shareholder vote on the Mentari Therapeutics merger scheduled for November 4, 2026

How the Period Went

InMed Pharmaceuticals reported a net loss of $2.33 million for the first quarter of fiscal 2026, representing a 35.0% expansion in losses compared to the $1.73 million deficit recorded in Q1-25. Pretax losses also increased, reaching $2.00 million for the quarter against $1.83 million in the previous year. Despite the deeper net loss, diluted earnings per share saw a marginal improvement to -$0.42 from -$0.44, likely reflecting changes in the weighted average shares outstanding. The financial results highlight the company's continued transition as a clinical-stage developer with no revenue-generating backlog as of the period end.

Margins and Profitability

The company’s profitability remains constrained by significant research and development outlays required for its cannabinoid-based pipeline. The $0.17 million year-over-year increase in pretax losses underscores the rising costs of clinical trials and the development of proprietary manufacturing technologies. Management is currently focusing on a strategic merger with Mentari Therapeutics to stabilize its long-term financial position. According to company reports from inmedpharma.com, a successful closing is expected to provide a cash runway extending into 2029, a critical factor for a firm currently reporting an operating loss of $2.33 million.

Business Overview

InMed Pharmaceuticals operates within the specialty and generic drug manufacturing sector, focusing on the therapeutic potential of rare cannabinoids. The company utilizes proprietary biosynthetic and manufacturing platforms to develop treatments for diseases with high unmet medical needs. Currently, InMed is at a pivotal corporate juncture; an annual general and special meeting is scheduled for November 4, 2026, to vote on the Mentari Therapeutics merger. This transaction is paired with a record date of November 5, 2026, for the distribution of Contingent Value Rights to existing shareholders, signaling a shift toward a combined entity structure.

Financial Context and Industry Landscape

With a market capitalization of $8.95 million, InMed is navigating the volatile micro-cap biotech space. The stock has demonstrated strong momentum with a 20.74% gain over the last month, though its RSI of 72.7 suggests technical overextension. In the broader cannabinoid pharmaceutical sector, peers are increasingly seeking consolidation to manage high R&D risks. InMed's projected $490.0 million capital infusion upon merger closing would significantly distance it from smaller cash-strapped peers. However, the company must continue to manage its cash position carefully until the targeted merger closing by the end of calendar year 2026.

InMed Pharmaceuticals Inc. share price · last month
Line chart of InMed Pharmaceuticals Inc.'s share price over the last month, from $13.30 on 5 Oct → $17.50 on 4 Nov; our story on 3 Nov at $1.63.

Up 973.6% since our story on 3 Nov: $1.63 when we broke it → $17.50 at the close on 4 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
5 Oct$13.30
6 Oct$13.30
7 Oct$13.30
8 Oct$13.30
9 Oct$13.60
12 Oct$13.60
13 Oct$13.30
14 Oct$13.10
15 Oct$13.30
16 Oct$13.20
19 Oct$13.65
20 Oct$13.40
21 Oct$13.60
22 Oct$13.30
23 Oct$14.40
26 Oct$15.90
27 Oct$15.90
28 Oct$15.99
29 Oct$16.25
30 Oct$16.00
2 Nov$16.30
3 Nov$16.80
4 Nov$17.50
Recent quarters and guidance
DateAnnouncementAmount
09 Sep 2026Q4 and FY 2026 financial resultsSource: inmedpharma.com–
06 May 2026Q3 FY 2026 financial resultsSource: inmedpharma.com–
11 Feb 2026Q2 FY 2026 financial resultsSource: investing.com$0.8 Million
06 Nov 2025Q1 FY 2026 financial resultsSource: investing.com$1.1 Million
23 Sep 2025Q4 and FY 2025 financial resultsSource: investing.com$1.3 Million
12 May 2025Q3 FY 2025 financial resultsSource: investing.com$1.3 Million
InMed Pharmaceuticals Inc. · financial snapshot
Share price$1.63
Market cap$9M
1-month price change+20.74%
SectorHealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by InMed Pharmaceuticals Inc. announcing its quarterly financial results for the period ended September 30, 2026.

Read the filing ↗

Track InMed Pharmaceuticals Inc. live

Get the next InMed Pharmaceuticals Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.